This program aims to develop anti-CD40 therapeutic monoclonal antibody for immuno-oncology. CD40 agonist mAb can upregulate MHCII, CD80, and CD86 on DCs and macrophages, promote CD8+ T cell activationin vivo, and likely alter TME myeloid component. Besides, induction of CD40 signaling on DCs us...
Iscalimab (CFZ533) is a fully human, blocking and non-depleting anti-CD40 monoclonal antibody. The purpose of this study was to investigate the efficacy and safety of Iscalimab in patients with Graves' hyperthyroidism. Methods: In total, fifteen patients with Graves' hyperthyroidism were ...
To further confirm that mFcγRIIB is responsible for the observed A20 crosslinking activities, we labeled A20 cells with an anti-mFcγRIIB blocking antibody prior to performing the reporter assays. Consistent with the role of mFcγRIIB engagement for anti-CD40 mIgG1 agonistic activity (Li ...
To simulate the effect of the lymph node microenvironment [52] on fadraciclib actions, we supplemented the CLL cells with B-cell activation (BCA) medium consisting of anti-CD40 monoclonal antibody, IL-4, and anti-IgM to mimic the T-cell stimulation and engagement of B-cell receptor signaling...
Chimeric agonist anti-mouse CD40 antibody (mIgG1, clone 3–23) sequences were obtained from professor Martin Glennie (University of Southampton, England). Codon optimization for the production in HEK (Homo sapiens) and CHO (Cricetulus griseus), as well as sub-cloning into pCEP4_A164 expression...
26, 27, 28 In addition, a strongly agonistic anti-CD40 antibody, CP-870,893, evaluated in phase 1 trials in patients with melanoma and other solid tumors, was found to be well tolerated and to have antitumor activity.29 Therefore, preclinical and early clinical data with CD40 antibodies ...
As the first second-generation anti-CD40L antibody to show efficacy in MS, frexalimab is thought to block the costimulatory CD40/CD40L cellular pathway necessary for adaptive (T and B cells) and innate (macrophages and dendritic cells) immune cell activation and function, without lymphocyte-...
The rationale for using GTKO) pigs to avoid anti-Gal antibody-mediated rejection, with additional human complement regulatory protein (hCD46) expression to suppress complement acti- vation, has been previously reported5. Similarly, the benefits of anti-CD154/CD40, aCD20 and mycophenolate mofetil (...
Chimeric agonist anti-mouse CD40 antibody (mIgG1, clone 3–23) sequences were obtained from professor Martin Glennie (University of Southampton, England). Codon optimization for the production in HEK (Homo sapiens) and CHO (Cricetulus griseus), as well as sub-cloning into pCEP4_A164 expression...
Careful clinical trial design and comprehensive patient monitoring will be essential for successful translation of these preclinical findings. Conclusion Our study provides compelling evidence for the therapeutic efficacy of combining RT with YM101 (a bispecific antibody that targets TGF-β and PD-L1) ...